named so because the 3D cells are nurtured in what looks like mini sacs hanging from the bottom of a specially designed plate.
3D Biomatrix is marketing the plates to contract research organizations, academic institutions, and pharma companies, especially those doing work in cancer research.
Schrader says the startup could really provide value to pharma. Cells grown in 2D environments are exposed to more oxygen than normal. Therefore, therapies that show promise with 2D cells often fail in later stage development.
With 3D Biomatrix, the pharma firms can save time by screening candidates in a 3D environment off the get go, Schrader says. Drug companies could potentially reach into their R&D vaults and rescreen candidates that were deemed unsuccessful with 3D cells, she says.
Schrader also says 3D testing will enable its customers to rely on fewer lab animals.
The company, which is already generating some revenue, is planning a full sales launch this month. Early users of the technology include Johnson & Johnson, Stanford University, and Alfred Hospital in Australia.
“It’s all about getting the word out, building out the brand,” Schrader says. “Also, if we’re yelling from the rafters how great your product is, you better make sure the product is as good as you’re yelling.”
The company has already raised $665,000 in seed funding from Ann Arbor SPARK and the Michigan Economic Development Corp. 3D Biomatrix is currently seeking $2 million in Series A funding.
Despite the difficult venture environment, Schrader says she is confident 3D Biomatrix will have no trouble finding investors. The startup has real products and real customers—“all signs of something good,” she says.
“My projections are realistic,” Schrader says. “I’m not worried.”
